CRO market to reach $24bn by 2010

By Emilie Reymond

- Last updated on GMT

Related tags: Contract research organization

The total contract research organisation (CRO) market is expected
to reach $24bn (€18bn) by 2010 as biopharma companies' spending on
outsourcing services continues to soar, new research reveals.

The pressure facing pharma firms to reduce time-to-market of new drugs coupled with a curb on spending has forced the industry to adopt alternative approaches to maintain productivity and profitability. Pharma firms are fast realising that bringing drugs to market more quickly is one way of countering a lower number of product approvals, as it allows them to bring in revenues from drug sales earlier. As a result, the reliance on services providers and in particular CROs has rocketed in the past few years and the total CRO market is now estimated at $14bn, and expected to grow at an annual rate of 14 to 16 per cent, according to market research firm Business Insights. The report called "The CRO Market Outlook: Emerging Markets, Leading Players and Future Trends" found that CROs provide substantial global capacity to drug developers and have become critical contributors to clinical activity. In addition, the research said clinical trials conducted by CROs are completed up to 30 per cent more quickly than those conducted in-house by pharma companies. Quintiles is the industry biggest player with 14 per cent of the global market share, followed by Covance and PPD, holding 10 per cent each. Meanwhile, the five largest CROs have increased their market share and now hold 45 per cent of the total market.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars